Teal Health has raised $22m, with plans to apply the proceeds towards advancing access to its approved at-home human papillomavirus (HPV) screening kit ahead of a federal guideline update that will require most US health plans to cover self-collection for cervical cancer from January 2027.
Bringing Teal’s total funds raised to date to $45m, the Series A financing round was led by .406 Ventures. Existing investors including Emerson Collective and Serena Ventures, along with new investor MPower Partners, also participated.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The California-based company’s Teal Wand sample collection device for HPV screening is packaged alongside a telehealth visit for patients, with test results delivered via a secure platform that also connects patients with follow-up care as required. Almost all cases of cervical cancer are caused by HPV, with 4,200 women in the US expected to die from the disease in 2026, as per the American Cancer Society (ACS).
Since securing US Food and Drug Administration (FDA) clearance in May 2025, Teal asserted that its device has screened thousands of women nationally. It has also been incorporated into national screening guidelines.
Teal said it is now setting its sights on rendering Teal Wand a routine preventative standard of care (SoC) option for cervical cancer screening. To meet this aim, the company plans to deploy the latest proceeds towards growing its existing array of payer, health system, employer, provider, and brand partnerships to broaden the test’s availability. Teal is also working to expand direct-purchase options for individuals and organisations.
Together, these channels are designed to move at-home screening beyond early adoption and establish it as a routine, widely available, and preferred part of preventive care nationwide, the company stated.
Teal’s intentions precede a significant guideline update from the US Department of Health and Human Services (HHS). The agency is updating its cervical cancer testing guidelines, a development which means that the majority of healthcare insurance plans must cover self-administered HPV tests from January 2027.
Teal Health’s CEO and co-founder, Kara Egan, commented: “Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort. Women need an accurate, trusted alternative that makes it easy to screen.
“This funding allows us to scale to meet the demand of patients and providers. It’s clear this option is preferred by women and now we can ensure everyone has a way to stay healthy.”
Research indicates that approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. According to the World Health Organization (WHO), if left untreated, persistent HPV infection of the cervix is attributable to an estimated 95% of cervical cancers.
Other companies offering self-administered HPV testing kits include Waters Corporation. The company’s Onclarity HPV self-collection kit obtained FDA clearance in April 2026.
